Company Description

Integrated Nanotherapeutics (INT) is a preclinical-stage company pioneering antigen-specific immune tolerance therapies using lipid nanoparticles (LNPs). Their proprietary drug delivery platform can deliver any type of drug modality in LNPs, either alone or in combination, with tunable cargo release profiles. The unique ability to co-deliver mRNA and small molecules enables a plug-and-play platform to treat autoimmunity at its root cause.